CorMedix Inc. Announces CMS Grants Transitional Drug Add-On Payment To DefenCath
Portfolio Pulse from Benzinga Newsdesk
CorMedix Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has granted a Transitional Drug Add-On Payment Adjustment (TDAPA) for its product DefenCath. This decision is expected to significantly enhance the reimbursement landscape for DefenCath, potentially improving its market penetration and sales.
April 19, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The CMS's decision to grant TDAPA for DefenCath is a significant positive development for CorMedix, likely to boost its revenue prospects and market presence.
The granting of TDAPA by CMS is a critical regulatory milestone that directly impacts the reimbursement and thus the commercial success of DefenCath. This decision is likely to lead to increased adoption and sales of DefenCath, positively affecting CorMedix's financial performance and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100